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Abstract
Background: The histologic grade (HG) of breast cancer is an established prognostic factor. The grade is usually
reported on a scale ranging from 1 to 3, where grade 3 tumours are the most aggressive. However, grade 2 is
associated with an intermediate risk of recurrence, and carries limited information for clinical decision-making.
Patients classified as grade 2 are at risk of both under- and over-treatment.
Methods: RNA-sequencing analysis was conducted in a cohort of 275 women diagnosed with invasive breast cancer.
Multivariate prediction models were developed to classify tumours into high and low transcriptomic grade (TG) based
on gene- and isoform-level expression data from RNA-sequencing. HG2 tumours were reclassified according to the
prediction model and a recurrence-free survival analysis was performed by the multivariate Cox proportional hazards
regression model to assess to what extent the TG model could be used to stratify patients. The prediction model was
validated in N = 487 breast cancer cases from the The Cancer Genome Atlas (TCGA) data set. Differentially expressed
genes and isoforms associated with HGs were analysed using linear models.
Results: The classification of grade 1 and grade 3 tumours based on RNA-sequencing data achieved high accuracy
(area under the receiver operating characteristic curve = 0.97). The association between recurrence-free survival rate
and HGs was confirmed in the study population (hazard ratio of grade 3 versus 1 was 2.62 with 95 % confidence
interval = 1.04–6.61). The TG model enabled us to reclassify grade 2 tumours as high TG and low TG gene or isoform
grade. The risk of recurrence in the high TG group of grade 2 tumours was higher than in low TG group (hazard ratio =
2.43, 95 % confidence interval = 1.13–5.20). We found 8200 genes and 13,809 isoforms that were differentially
expressed between HG1 and HG3 breast cancer tumours.
Conclusions: Gene- and isoform-level expression data from RNA-sequencing could be utilised to differentiate HG1
and HG3 tumours with high accuracy. We identified a large number of novel genes and isoforms associated with HG.
Grade 2 tumours could be reclassified as high and low TG, which has the potential to reduce over- and
under-treatment if implemented clinically.
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Background
Histologic grade (HG) is considered as one of the best
established prognostic factors in breast cancer diagnos-
tics [1]. According to the Nottingham grading system,
breast cancer is categorised to three HGs depending on
the degree of tumour cell differentiation: well differen-
tiated (grade 1), moderately differentiated (grade 2) and
poorly differentiated (grade 3) [2, 3]. The grading system
assesses three dimensions: tubule formation (tubularity),
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nuclear pleomorphism (nuclearity) and mitotic count.
Each component is categorised as a score from 1 to 3. The
overall grade is determined by the sum of the scores from
the three components. Tumours with a higher grade are
associated with a lower survival rate [4].
A morphological assessment of biological characteris-
tics provides important information related to the clinical
behaviour of breast cancer. Patients with grade 3 tumours
are recommended for adjuvant chemotherapy, whereas
patients with grade 1 tumours are often oestrogen recep-
tor (ER) positive, and thus amenable for a less toxic
endocrine therapy [1]. In general, half of the cases are
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assigned to grade 1 or 3. Grade 2 tumours account for
the other half and they are associated with an intermedi-
ate risk of recurrence, which is not informative for clinical
decision-making [5]. Furthermore, inter-pathologist vari-
ability in the morphological assessment contributes to a
degree of uncertainty in tumour grade classification [6, 7].
In the last decade, genome-wide gene expression pro-
filing methods have introduced new ways for tumour
classification using molecular signatures. The genomic
grade index (GGI) was previously proposed as a method
to stratify ER-positive grade 2 tumours into two groups
[5], which could be potentially integrated to the current
HG system. GGI is based on a 97-gene signature with gene
expression abundances quantified by microarray technol-
ogy. A large cohort study revealed that GGI provides
significant prognostic information beyond clinical char-
acteristics including tumour size, lymph node status and
HG [8] in ER-positive tumours. The study indicated that
combining molecular signatures with HG may improve
the prognostic power.
The 97-gene biomarker panel used for GGI was
developed based on microarray data at the gene level.
Recently next-generation sequencing of RNA (RNA-seq)
has emerged as the de facto standard for gene-expression
profiling, also enabling quantification of gene expression
at both gene and isoform level. Isoform-level gene expres-
sion data has the potential to provide further insight
and prognostic information beyond gene-level expres-
sion data. For example, it has been found that different
isoforms may have different molecular functions [9]. In
prostate cancer, it has been reported that two isoforms of
KLF6 lead to increased cell growth and an increased risk
of prostate cancer [10].
To improve patient stratification and to enable better
personalised care for breast cancer patients, we devel-
oped methods based on RNA-seq data to determine the
transcriptomic grade (TG) of tumours. The TG model
we propose dichotomises tumours into a high grade and
low grade, thus providing improved stratification of the
intermediate HG2 patients. The proposed method has the
potential to reduce both over- and under-treatment of
HG2 patients. We also characterise the molecular basis of
HG by investigating to what extent RNA-seq gene- and
isoform-level expression are associated with HG.
Methods
Data sets and subjects
Clinseq
Study participants were 275 females diagnosed with pri-
mary invasive breast cancer from the Clinseq study (Clin-
ical Sequencing of Cancer in Sweden; http://clinseq.org/)
[11]. The Clinseq breast cancer study comprises two
Swedish cohorts, Libro-1 [12] and Karma [13]. Study
participants from Karma were recruited perspectively
from 2012 in Stockholm South General Hospital (in
Swedish: Södersjukhuset). Study participants from Libro-
1 were recruited retrospectively among patients who
underwent surgery between 2001 and 2008 at the
Karolinska University Hospital (in Swedish: Karolinska
Universitetssjukhuset) and were alive in 2009. The study
is approved by the Ethical Committee of the Karolin-
ska Institute (reference number 2013/1833-31/2) and all
participants provided written informed consent.
Primary tumour tissues were collected from the partici-
pants and stored in the Karolinska Institute Biobank. The
HGs of cancer were evaluated by pathologists based on
the Nottingham grading system [2, 3]. Grade information
was extracted from the patient pathology records. Clinical
and follow-up information was retrieved through a link to
the Swedish national breast cancer register, the Informa-
tion Network for Cancer Care [14] and the regional can-
cer centres [15]. Clinical biomarkers – ER, progesterone
receptor (PR), human epidermal growth factor receptor
2 (HER2) and KI67 – were measured by an immunohis-
tochemistry assay. ER and PR status were determined as
positive if comprising more than 10 % of the correspond-
ing nuclear staining. The cut-off for KI67 was 20 % posi-
tively stained tumour cells. HER2 status was classified as
positive if a fluorescent in situ hybridisation (FISH) result
indicated amplification or, in the absence of a FISH result,
if the sample was graded 3+ by the immunohistochemistry
assay.
The Cancer Genome Atlas
We also used RNA-seq data from The Cancer Genome
Atlas (TCGA) (http://cancergenome.nih.gov/). Unaligned
RNA-seq data (FASTQ format) of 1126 invasive breast
carcinoma samples were downloaded in June 2014 after
approval from the TCGA data access committee (dbGAP
project ID 5621). The grade information was manu-
ally extracted from copies of patient pathology reports
provided by TCGA. The HGs of TCGA breast cancer
patients were diagnosed with multiple grading systems.
To ensure the consistency with our study population, only
487 female breast cancer patients from TCGA whose HG
was diagnosed by the Nottingham grading system and
for which all three subcomponent scores were available
were included in this study. We acknowledge that because
scoring was by multiple pathologists across multiple insti-
tutions, that there may still be some variation in grades.
Bioinformatic preprocessing of the RNA-seq data used
identical methods as for the CLINSEQ data set (described
below).
RNA-sequencing
RNA from breast tissue was extracted from fresh frozen
breast tumour tissues that were removed during surgery.
RNA was extracted using an AllPrep DNA/RNA/Protein
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mini kit (Qiagen, Germany). RNA was assessed using
Bioanalyzer (Agilent, US) to ensure high quality (RNA
integrity number >8). Then, 1 μg of total RNA was
used for rRNA depletion using RiboZero (Illumina, US)
and stranded RNA-seq libraries were constructed using
a TruSeq Stranded Total RNA Library Prep Kit (Illu-
mina, US). Then 2 × 100 paired-end sequencing was
performed on an Illumina HiSeq 2500 (Illumina, US)
at the Science for Life Laboratory (Stockholm, Swe-
den). The insert sized ranged from approximately 50
to 300 bp. The resulting RNA-seq reads were aligned
to the reference genome (GRCh37.73) using STAR
[16] version-2.4.0e39 with the following parameters:
-outSAMmapqUnique 50, to set the maximum align-
ment quality score to 50; -outSAMunmapped Within,
to include unmapped reads in the resulting SAM file;
-chimSegmentMin 20 to require that a minimum of
20 bases map to each end of a chimeric transcript (out-
put in a separate file) and -outSAMattributes NH
HI AS nM NM MD XS to include additional attributes
in the SAM file. Gene-level expression was quantified
using HTSeq-count [17] version-0.6.040 with the fol-
lowing parameters: -stranded = no and -mode =
intersection-nonempty for counting reads using
the default alignment quality filter threshold of 10.
There are 20,477 genes in the reference genome and
144,027 isoforms in the reference transcriptome. There
were 18,795 genes with non-zero read counts. Isoform-
level expression was quantified using Sailfish version 0.6.3
[18] and ENSEMBL version 75 with the following param-
eters: -p 16 -k 20 to use 16 threads and a k-mer size
of 20. For each sample, Sailfish version 0.6.3 was run
with default parameters except for library type, which was
set to --libtype”T=PE:S=AS:O=><” for paired-end
second-read mapping to the antisense strand and inwards
orientation. The default bias correction was applied. Iso-
forms were filtered if they failed to achieve counts per
million of 1 in 75 % of the samples. After filtering, there
were 42,718 isoforms left for downstream analysis.
RNA-seq read counts were scaled logarithmically by
the variance stabilising transformation implemented in
DESeq2 for prediction modelling [19]. For differen-
tial expression (DE) analysis, read counts were nor-




We applied the multivariate elastic-net penalised logistic
regression model [22] for prediction of tumour grade with
either transcriptome-wide gene- or isoform-level nor-
malised expression values as predictors. The elastic-net
method is implemented in the R package glmnet [23].
The tumour grade model was trained on HG1 and HG3
tumours and we estimated separate models for gene- and
isoform-level transcriptomic data. The two models are
referred to as TG at gene level (TG-Gene) and at isoform
level (TG-Iso).
A nested cross-validation (CV) procedure was used
to estimate prediction performance while also optimis-
ing model parameters (alpha and lambda). For outer
CV, class-balanced Monte-Carlo CV was performed (100
rounds). The training/test set ratio was 90 %/10 %.
Patients with grade 3 or grade 1 were balance strati-
fied into the training and test sets. The CV samples
were identical across the evaluation of different models
to ensure accurate model comparison. The parameters
were optimised empirically based on the outer CV loop
training set in the inner CV (10 × tenfold CV). The
alpha parameter was evaluated on a grid at the follow-
ing points: 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.5, 0.7
and 0.9. The best alpha and lambda were chosen based on
minimising the average misclassification error. The prob-
ability of being HG3 was calculated for outer CV test
set observations from the optimised model in each CV
round.
Receiver operating characteristic (ROC) curves of TG
against true HGs were constructed. The area under the
ROC curve (AUC) and 95 % confidence interval (CI) were
generated to compare model performance. The AUCs of
ROC curves were compared by the DeLong test [24]. The
decision boundary was determined at the point closest
to the top-left part of the ROC curve using the pROC
package for R [25]. HG2 patients were classified as high
risk (HG2-High) if their predicted probability was larger
than or equal to the cut-off point; otherwise, patients were
classified as HG2-Low.
TG based on subcomponents of HG
We also developed prediction models based on separate
modelling of the subcomponents of HG at gene- and
isoform-level (SC-Gene and SC-Iso). The procedures for
parameter optimisation and CV were the same as for
the TG-Gene and TG-Iso models; however, they were
conducted for each component separately. The three sub-
components of HG (tubularity T, nuclearityN andmitotic
countM) were predicted by an elastic-net penalised linear
regression model. For each outer CV, 90 % of the sample
were selected in the training set. The proportions of HG1
and HG3 were kept as in the whole sample set. The linear
multivariate model was built guided by sub-scores 1, 2 and
3. The final score was defined as the sum of the predicted
subcomponent scores.
Genomic Grade Index
For comparison, we also implemented the previously
reported GGI method [5]. According to Sotiriou’s study,
the top 128 DE probes of 97 unique genes were selected
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to calculate GGI, and out of these we could match 96 gene
symbols to genes in our data set.We applied the GGI algo-
rithm as described in the original article [5].We applied an
identicalMonte Carlo CV procedure for the GGImodel as
described in the previous section. Standardisation param-
eters (scale and offset) were generated for each training
set. Then the GGI of samples in the test set were standard-
ised using parameters from the training set, ranging from
−1 to 1. AUC and 95 % CI were calculated using the ROC
curve on the GGI against the true HG.
Validation in the secondary data set
The prediction models (TG-Gene, TG-Iso, SC-Gene and
SC-Iso) were validated with the TCGA breast cancer data
set [26]. The prediction models were estimated based on
the Clinseq data set where model parameters (alpha and
lambda) were optimised by tenfold CV for 100 times. The
parameters alpha and lambda were chosen so that the
mean of deviance residuals was minimised. To reduce any
potential batch differences between them, the data sets
were mean-centred before analysis. According to the GGI
method, the index was standardised within each data set.
Hence, cross data set validation does not apply to the GGI
method.
Survival analysis on HG and TG
The recurrence-free survival (RFS) rate was compared
among patients with different HGs to investigate whether
grade is an indicator of prognosis in this study population.
The predicted high TG and low TG groups within grade 2
tumours (HG2-High and HG2-Low) were also compared.
A recurrence event is considered to be a local or regional
tumour relapse, distant metastasis, contralateral tumour
or death by any cause. Patients who died before experienc-
ing a tumour metastasis were assumed to have had unde-
tected metastasis before death [27]. The time to event is
measured from the diagnostic date to the date of the first
documented local or regional relapse, distant metastasis,
contralateral tumour, death or last follow-up.
A Kaplan–Meier curve was used to estimate the sur-
vival outcomes and groups were compared with the non-
parametric log-rank statistic. Data from the two data sets
(Clinseq and TCGA) were pooled together. Univariate and
multivariate Cox proportional hazards regression mod-
els were fitted at time-on scale. Unadjusted and adjusted
hazard ratios (HRs) and 95 % CI were calculated. In the
multivariate Cox regression model, we adjusted for age,
tumour size, lymph node status and ER status, and strati-
fied by data set. Age was treated as a continuous variable.
Tumour size was dichotomised based on the diameter of
the tumour as ≥20 mm or <20 mm. Lymph node sta-
tus was dichotomised as with or without lymph node
metastases. Proportional hazards assumptions were con-
firmed using Schoenfeld residuals. The survival analysis
was conducted using standard functions implemented in
R [28, 29].
DE analysis on HGs and subcomponents of grades
RNA-seq data were compared among patients with dif-
ferent HGs and subcomponents of grades to determine
DE genes and isoforms. Read counts were transformed
to log-counts with a precision weight by estimating the
mean-variance relationship (voom) [30]. Empirical Bayes
moderated t-statistics was applied to analyse DE isoforms.
The Benjamini and Hochberg false discovery rate (FDR)
was used to adjust for multiple testing [31]. The DE of
genes or isoforms was defined as those with FDR-adjusted
p < 0.05. The DE analysis was performed by functions in
the R package limma [32].
Pathway analysis
A pathway enrichment analysis of DE genes based on
the Reactome database (http://www.reactome.org/) [33]
was conducted with R package ReactomePA [34]. Path-
way overrepresentation was tested by a hypergeometric
model [35].
PAM50 subtyping
PAM50 intrinsic subtypes [36] were assigned using the
nearest shrunken centroid classifier [37] in the Clinseq
data set. The R package pamr was utilised to train the
classifier. Optimisation (amount of shrinkage) was deter-
mined by tenfold CV selecting the parameter value based
on theminimal classification error. The subtypes in TCGA
were referred to their original breast cancer publication
[26]. The normal-like subtype was not included as the
clinical relevance for this subtype has been questioned
[38]. The distributions of subtypes between HGs and pre-
dicted groups were compared by a chi-squares test or
a Fisher exact test if the expected value in any cell was
smaller than 5.
Results
Adescription of the clinical characteristics andHGof sub-
jects in both the Clinseq and TCGA data sets is listed in
Table 1. The distributions of HGs in the two data sets
were similar (p > 0.05, chi-squares test). The mean of the
patients’ ages was not statistically different across the two
data sets (p > 0.05, Student’s t-test). There were more
tumours with a larger size and positive lymph node in the
TCGA data set (p < 0.05, chi-squares test). The distribu-
tions of ER, PR and HER2 between the two data sets were
not different.
HG can be predicted from RNA-seq gene expression
profiles
We developed prediction models based on HG3 and HG1
individuals, using RNA-seq data at both gene and isoform
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Median age (range) 61 (28–94) 57 (26–90)
Histologic grade
Grade 1 (%) 39 (14.2 %) 64 (13.1 %)
Grade 2 (%) 121 (44.0 %) 228 (46.8 %)
Grade 3 (%) 115 (41.8 %) 195 (40.0 %)
Tumour size
≥20 mm (%) 150 (54.6 %) 317 (65.1 %)
<20 mm (%) 125 (45.5 %) 170 (34.9 %)
Lymph node status
Positive (%) 39 (14.2 %) 260 (53.4 %)
Negative (%) 136 (85.8 %) 227 (46.6 %)
ER status
Positive (%) 231 (84.0 %) 384 (78.9 %)
Negative (%) 42 (15.3 %) 102 (20.9 %)
NA (%) 2 (0.7 %) 1 (0.2 %)
PR status
Positive (%) 175 (63.6 %) 334 (68.6 %)
Negative (%) 98 (35.6 %) 151 (31.0 %)
NA (%) 2 (0.7 %) 2 (0.4 %)
HER2 status
Positive (%) 44 (16.0 %) 60 (12.3 %)
Negative (%) 225(81.8 %) 274 (56.3 %)
Equivocal (%) – 108 (22.2 %)
NA (%) 6 (2.2 %) 45 (9.2 %)
KI67 statusa
Positive (%) 131 (47.6 %) –
Negative (%) 121 (44.0 %) –
NA (%) 23 (8.4 %) –
ER oestrogen receptor, NA not applicable, PR progesterone receptor, TCGA The
Cancer Genome Atlas
aMeasurement of KI67 is not available for the TCGA data set
level (TG-Gene, TG-Iso, SC-Gene and SC-Iso). The num-
bers of predictors selected in each final model (TG-Gene
in Clinseq, TG-Gene in TCGA, TG-Iso in Clinseq and
TG-Iso in TCGA) were 427, 96, 112 and 255, respec-
tively listed in Additional file 2. The GGI method was also
implemented for comparison. Prediction performance, as
assessed by ROC curves, was found to be similar for all
five models within each data set (Fig. 1a, b). In the Clinseq
data set, the AUC of the GGI method was higher than for
the SC-Iso model (p < 0.05, DeLong test). The AUC of
the ROC curve for the SC-Gene, SC-Iso, TG-Gene and
TG-Iso models showed no statistical difference (p > 0.05,
DeLong test). For the TCGA data set, the AUCs of the SC-
Gene and the SC-Iso models were higher than for any of
the TG-Gene, GGI and TG-Iso models (p < 0.05, DeLong
test).
Next, we assessed the concordance of the five different
models in the classification of HG1 andHG3 by predicting
all observations by the fittedmodels. The results indicated
a relatively high degree of concordance across all methods
(Additional file 1: Figure S1).
To validate the prediction models further, they were
estimated based on the Clinseq data set, and the grade
in the TCGA data set was predicted. The ROC curves of
the models are in Fig. 1c. All of the models achieved high
accuracy (AUC = 0.97), and vice versa, when models were
trained in TCGA and predicted in Clinseq (Additional
file 1: Figure S8).
We then investigated if patients with a grade 2 tumour
were classified consistently into high and low TG groups
by the prediction models. The concordance of the mod-
els is displayed in Fig. 1d. Among the five models, 76.4 %
(252 of 330 individuals) of the HG2 patients were classi-
fied consistently (HG2 patients from both the Clinseq and
TCGA data sets). Given that patients clinically classified
as HG2 are considered as intermediate in current clinical
practice, with little or no impact on clinical decision-
making due to their intermediate status, 76 % consistency
across multiple different models is to be considered as a
relatively high degree of concordance.
Modelling of HG subcomponents
To investigate if the different subcomponents of histo-
logical grade were different on a gene expression level,
we developed prediction models for subcomponents of
grade (see ‘Methods’) and evaluated the prediction perfor-
mance. The distribution of subcomponent scores of HG
are summarised in Table 2. The ROC curves of three com-
ponents from the SC-Gene and SC-Iso models for the
Clinseq and TCGA data sets are illustrated in Additional
file 1: Figure S4. We found that the molecular informa-
tion in the RNA-seq data (gene or isoform level) enabled
a good ability to classify score 1 and score 3 individuals in
terms of mitotic count (AUC = 0.92, SC-Gene model for
the Clinseq data set), while the classification of score 1 and
score 3 for the tubularity and nuclearity components was
substantially lower (AUC= 0.68 andAUC= 0.76, SC-Gene
model for the Clinseq data set), suggesting that the molec-
ular difference between score 1 and score 3 individuals for
these components is limited.
RFS is different among HGs and TGs
To evaluate if the RFS rate was associated with HGs, we
compared RFS between HG groups (Fig. 2a). The sur-
vival analysis was carried out on the Clinseq and TCGA
data sets combined. Forest plots from the univariate and
multivariate Cox regression models for each data set are
displayed in Additional file 1: Figures S10 and S11. No
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Fig. 1 Prediction models comparison. ROC curves of CV on five models: GGI, TG-Gene, TG-Iso, SC-Gene and SC-Iso for a the Clinseq data set and
b the TCGA data set. AUC estimates and 95 % CI of ROC curves are listed for each model. c Cross-data set validation of multivariate prediction
models (TG-Gene, TG-Iso, SC-Gene and SC-Iso). Models were estimated based on the Clinseq data set, and grade in the TCGA data set was predicted.
d Predictions of HG2 tumours by five models for all observations in the Clinseq and TCGA data sets. AUC area under the ROC curve, CI confidence
interval, CV cross-validation, GGI genomic grade index, ROC receiver operating characteristic, TCGA The Cancer Genome Atlas
obvious bias was found between the two cohorts. The
median follow-up time was 3.6 years. The RFS rate was
found to be different between HG groups (p = 0.017, log-
rank test). In the Cox regression model, the unadjusted
HR of grade 3 against 1 was 2.62 (95 % CI = 1.04–6.61).
The adjusted HR comparing grade 3 with grade 1 was not
statistically significant (Table 3).
Table 2 Summary of HG and subcomponents of subjects
Grade Tubularity Nuclearity Mitotic counts
Clinseq
1 39 18 4 119
2 121 55 136 73
3 115 198 131 79
Missing 0 4 4 4
TCGA
1 64 12 24 197
2 228 91 224 119
3 195 337 195 123
Missing 0 47 44 48
HG histologic grade, TCGA The Cancer Genome Atlas
Next, we compared RFS rates between TGs of HG2
patients to determine if there were any evidence that the
TG models provided prognostic information. RFS curves
of HG2-High and HG2-Low groups for all five TGmodels
were compared (Additional file 1: Figure S2). Groups pre-
dicted by the GGI, TG-Gene and TG-Isomodels indicated
statistically significant differences in RFS rate (Table 3,
p < 0.05, log-rank test).
Figure 2b shows the corresponding Kaplan–Meir curves
of HG2-High and HG2-Low predicted by the TG-Gene
model. The unadjusted HR of HG2-High versus HG2-
Low was 2.43 (95 % CI = 1.13–5.20). When adjusted for
age, tumour size, lymph node status and ER status, HR
increased to 2.50 (95 % CI = 1.14–5.50).
Association between HGs and PAM50 subtypes
We then investigated the association between HGs and
the PAM50 intrinsic gene signature to determine if the
subtype distribution was similar when stratified by HG
and TG, focusing on reclassified HG2 tumours. Subtype
proportions for patients stratified by grade predicted by
the TG-Gene model are displayed in Fig. 2c. The other
prediction models provided highly similar results (see
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Fig. 2 TG-Gene model predictions in HG2 tumours (Clinseq and TCGA data sets combined). a Kaplan–Meir curves of RFS by HGs. b Kaplan–Meir
curves of RFS between groups predicted by the TG-Gene model (HG2-High and HG2-Low). c PAM50 subtype distribution of HGs and predicted
groups in HG2. d KI67 distribution. HG histologic grade, RFS recurrence-free survival
Additional file 1: Figure S2). Samples from the Clinseq and
TCGA data sets were combined. The distributions of sub-
types between HGs were different (chi-squares = 323.3,
p < 0.001). We found the distribution of subtypes in the
HG2-Low group were similar to HG1 (p > 0.05, Fisher’s
exact test). However, the subtype distributions for HG2-
High were found to be different to HG3 (chi-squares =
67.3, p < 0.001).
The distribution of PAM50 subtypes in the TG-High
and TG-Low groups of all the samples was compared to
HG3 and HG1, respectively. In the TG-Gene model, the
distribution of subtypes in TG-Low was similar to HG1
(p > 0.05, Fisher’s exact test). The subtype distribution
in TG-High was found to be different to HG3 (p = 0.02,
chi-squares test). See Additional file 1: Figure S3 for the
subtype distribution across all five prediction models.
Within subtype luminal A, the RFS rates of TG-High
and TG-Low stratified by the TG-Iso model were differ-
ent (p = 0.028, log-rank test, Additional file 1: Figure S9).
Suffering from the limited number of recurrent events
observed, the results were not consistent among differ-
ent models. A survival analysis could not be conducted in
other subtypes due to the limited sample size and limited
number of events.
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Table 3 p value of log-rank test and HRs of Cox regression on RFS comparing breast cancer patients with different HGs and predicted
groups in HG2 tumours
N Events Log-rank test HR unadjusteda HR adjustedb
(p value) (95 % CI) (95 % CI)
Histologic grades
HG1 98 6 0.017∗ 1.00 (Reference) 1.00 (Reference)
HG3 294 44 2.62 (1.04–6.61)∗ 2.02 (0.76–5.40)
GGI
Low risk 223 12 0.010∗ 1.00 (Reference) 1.00 (Reference)
High risk 110 15 2.64 (1.23–5.70)∗ 3.04 (1.35–6.81)∗
TG-Gene
Low risk 228 13 0.018∗ 1.00 (Reference) 1.00 (Reference)
High risk 105 14 2.43 (1.13–5.20)∗ 2.50 (1.14–5.50)∗
TG-Iso
Low risk 216 11 0.014∗ 1.00 (Reference) 1.00 (Reference)
High risk 117 16 2.53 (1.17–5.47)∗ 2.64 (1.20–5.79)∗
SC-Gene
Low risk 198 14 0.584 1.00 (Reference) 1.00 (Reference)
High risk 117 11 1.25 (0.56–2.78) 1.23 (0.54–2.77)
SC-Iso
Low risk 208 14 0.393 1.00 (Reference) 1.00 (Reference)
High risk 107 11 1.41 (0.64–3.14) 1.45 (0.65–3.24)
GGI genomic grade index, sHR hazard ratio, RFS recurrence-free survival
aHR unadjusted, only stratified by data set
bHR adjusted for age, tumour size, lymph node status and ER status, stratified by data set
∗p < 0.05
TG-High patients had higher proliferation levels
We further analysed the relationship between KI67, a pro-
liferation marker, and HGs and TGs (Fig. 2d). The KI67
level was associated with HGs (p < 0.001, ANOVA
test). Comparing the KI67 of predicted groups within
HG2, the mean of HG2-High is higher than HG2-Low
(p < 0.001, t-test). Comparing the KI67 level between
the TG-High and TG-Low groups predicted from all of
the patients, the mean of KI67 was higher in TG-High
than TG-Low (p < 0.001, t-test). The results were consis-
tent among the five models (Additional file 1: Figures S2
and S3).
DE genes and isoforms among HGs are associated with cell
cycle
In the Clinseq data set, 8200 genes and 13,809 isoforms
were found to be DE (FDR< 0.05) between HG1 and HG3
tumours, while there were fewDE genes detected between
HG1 and HG2 patients (Fig. 3a, b). If tumour size and
lymph node status were adjusted, there were 7928 genes
and 13,059 DE isoforms. In 3919 DE genes, the average
expression level in HG3 was higher than that for HG1. In
contrast, the average expression level in HG1 was higher
than for HG3 in the other 4009 genes.
The numbers of DE genes between the HG2-High and
HG2-Low groups for the fivemodels (GGI, TG-Gene, TG-
Iso, SC-Gene, and SC-Iso) were found to be 4091, 3750,
2935, 3750 and 3821, respectively. Between these sets,
there were 1864 genes in common. Comparing the DE
genes between HG2-High and HG2-Low to the 8200 DE
genes between HG1 versus HG3, there were 2893, 2728,
2274, 2945 and 3001 genes in common. The large num-
ber of DE genes indicate that HG2-High and HG2-Low
stratified by the TG models are biologically distinct.
The 13,809 DE isoforms between HG1 and HG3 were
mapped to 9020 unique genes. Of these, 6052 already
showed DE at the gene level (and were included in the
8200 DE genes). Hence, 2968 isoforms (of 2215 genes)
were found to be DE and were not identified in the gene-
level analysis (Fig. 3c). Pathway analysis revealed that
most DE genes between HG1 and HG3 were enriched in
cell-cycle pathways (Fig. 3d).
For 444 genes, DE isoforms of the same gene were asso-
ciated with HG in opposite directions. This phenomenon
was observed in 783 genes in the TCGA data set. Of
these, 188 were common across the two data sets. For
instance, there were six DE isoforms of gene CD44 iden-
tified in both data sets. The average expression level in
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Fig. 3 DE analysis. a Venn diagram of DE genes between HGs. b Venn diagram of DE isoforms. c Overlaps of DE genes and isoforms between HG1
and HG3. d Top ten enriched pathways of DE genes. Count is the number of genes found in each pathway. DE differential expression or differentially
expressed, FDR false discovery rate, HG histologic grade, p.adjust Benjamini and Hochberg FDR corrected p value of the overrepresentation test.
grade 1 tumours was lower than for grade 3 tumours
in one isoform [Ensemble: ENST00000279452]. However,
the average expression level of the other five isoforms
was higher in HG1 than HG3. The expression levels of
the CD44 isoforms are illustrated in Additional file 1:
Figure S6. Transcripts for this gene are determined by
a complex alternative splicing mechanism that results in
many functionally distinct isoforms. An association with
CD44 variant isoforms in the progression of head and
neck squamous cell carcinoma has been reported [39].
For the three subcomponents of HG—tubularity, nucle-
arity and mitotic count—the numbers of DE genes
between 1 and 3 were 1613, 165 and 10,617, respectively
(see Additional file 1: Figure S5). The top overrepresented
pathways for each component are listed in Additional
file 1: Table S1. We found that cell-cycle pathways were
also enriched among genes that were DE in tubularity
and mitotic count. DE genes associated with nuclearity
were found to be associated with the neurone system. This
unlikely association might be a reflection of the modest
number of DE genes. Interestingly, the scores of the three
subcomponents of grade did not contribute equally to HG
(see previous section), and they were also associated with
different molecular mechanisms.
Frequently selected predictors in prediction model are DE
between HGs
To investigate if a smaller biomarker panel for prediction
of TG could be defined, we tested whether the most fre-
quently selected predictors (genes) over CV rounds could
be utilised in a model and provide equally good predic-
tions as the full model. The Clinseq TG-Gene model was
cross-validated for 100 CV rounds. In each CV round,
a regularised (elastic-net) regression model was fitted.
Like the lasso regression model [40], the elastic-net model
shrinks some of the coefficients to exactly zero, effec-
tively performing variable selection. Here we utilised the
property of variable selection in this model, but as we
were concerned with robustness of the variable selection,
we relied on the subsampling of the data that occurred
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during CV and ranked variables by how frequently they
were selected over the CV rounds. We found that 10,454
genes were selected at least once. Ten gene sets with genes
that were selected ≥99 to ≥90 (out of 100) CV rounds
were fitted in ridge-penalised logistic regression and reg-
ular logistic regression models using the Clinseq data set,
with the TCGA data set as an external test set to evaluate
prediction performance (Additional file 1: Figure S7). A
biomarker panel based on the 34 most frequently selected
genes (the grade 34 panel) was the smallest panel that
also provided maximal prediction performance when pre-
dicting TCGA individuals (AUC = 0.963, 95 % CI =
0.943–0.983; see also Additional file 1: Figure S7).
All of the 34 genes were DE between HG1 and HG3
(FDR adjusted p < 0.05), and this gene set was mainly
associated with cell-cycle-related pathways. The expres-
sion levels of the grade 34 panel plotted together with HG
and TG also revealed visually distinct patterns of expres-
sion between TG groups (Fig. 4). The grade 34 panel
provides a candidate set of genes that could be used to
determine the TG in situations when transcriptome-wide
data are not available. A list of the 34 genes is provided in
Additional file 1: Table S2.
Discussion
Sequencing-based cancer diagnostics may become rou-
tine in the clinic in the near future. This will enable more
precise and accurate diagnosis of patients, and is likely
to lead to a reduction of both over- and under-treatment
of patients while also improving outcomes. Results from
this study indicate that HG could be replaced by TG
based on RNA-seq profiling. TG would also provide addi-
tional benefits through improved patient stratification by
dichotomising the patients into low and high TG, and
eliminating the intermediate group of HG2 patients. To
our knowledge, this is the first comprehensive transcrip-
tomic analysis of HG based on RNA-seq data where both
gene- and isoform-level expression were considered.
Morphological and histologic classifications of breast
cancer have been implemented in clinical settings for
decades. The well-established association between dis-
ease progression and HGs [4] was confirmed in this study
population. Our finding supports that HG is a prognos-
tic indicator of breast cancer. In this study, we further
provided molecular insight into HG. We confirmed pre-
vious findings that HG1 and HG3 tumours had distinct
gene expression profiles [5]. Thousands of additional DE
genes between HG1 and HG3 were identified compared
to what was previously reported. We found the differ-
ence between HG1 and HG2 was ambiguous (Fig. 3a).
This indicates that some HG2 patients have a similar
expression profile as HG1 patients, suggesting that they
may in fact be misclassified in the clinic, which could lead
to over-treatment.
We demonstrated that multivariate prediction models
using gene- or isoform-level RNA-seq data can be applied
to discriminate betweenHG1 andHG3 tumours with high
accuracy, and for further stratification of HG2 tumours
into high and low TGs. Classification accuracy of the
prediction models assessed by CV is high, with AUC
= 0.975 (95 % CI = 0.968–0.983) in the SC-Iso model
(Fig. 1a). The prediction model was also validated in a sec-
ondary data set (Fig. 1c) with equally good predictions
(AUC = 0.970, 95 % CI = 0.951–0.990). Predictions for
HG2 show a high degree of concordance across the five
methods, while GGI has the most distinct profile com-
pared to the other four predictionmodels. The differences
in RFS rates between HG2-High and HG2-Low stratified
by the TG-Genemodel were statistically significant (Fig. 2,
adjusted HR = 2.61, 95 % CI = 1.20–5.65). The distribu-
tions of PAM50 subtypes between TG and HG groups
were found to be similar, providing further evidence that
the TG model provides results that are concordant with
HG (Fig. 2c and Additional file 1: Figure S3). Usually,
luminal A is associated with lower grade and luminal B
with higher grade [38]. The TG model classified HG2
patients so that the great majority of luminal A patients
were labelled as TG-Low, while the great majority of lumi-
nal B cases were classified as TG-High. Moreover, the
TG-Iso model was able to stratify luminal A patients into
two groups with different recurrence rates (p = 0.028,
log-rank test). The proliferation indicator KI67 was also
assessed in the two TG groups, and we found that it was
higher in the predicted HG2-High group compared with
the HG2-Low group. Our results suggest that our models
are robust and consistent for prediction of TG and highly
concordant in classification of HG1 and HG3.
In this study, we validated the GGI method proposed by
Sotiriou et al. [5] for prediction of HG. We found that the
GGI 97-gene signature had accuracy similar to the RNA-
seq-based models developed in this study. However, GGI
was indeed developed based on microarray technology
and based on a relatively small amount of study material
consisting of only ER-positive samples. The limitation of
both the microarray technology and sample size was also
reflected in the modest number of DE genes (97) detected
in that study. In contrast, based on our RNA-seq data, we
found 8200 DE genes. Applying the GGI algorithm to all of
the 8200 DE genes would most likely introduce noise into
the model and degrade the prediction accuracy of GGI. In
developing the TG model, we applied a statistical learn-
ing approach based on regularised regression to select the
most predictive genes, a strategy that is expected to out-
perform variable selection by filtering on p values fromDE
analysis. Moreover, RNA-seq data are expected to be less
noisy compared to microarray-based expression profiling
[41, 42], and therefore, they also have the potential to pro-
vide improved diagnostic models and biomarker panels.
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Fig. 4 Heat map of 34 frequently selected genes in the TG-Gene model. In the Clinseq data set, the TG-Gene model was cross-validated 100 times to
optimise parameters. In 100 rounds of CV, 34 genes were selected in the models in more than 92 out of the 100 CV rounds. Value of colour key is
log2 (normalised RNA-seq count). ER oestrogen receptor, PR progesterone receptor, RNA-seq RNA sequencing
In this study, we found that the various methods (GGI
versus TG) performed highly similarly, which is a positive
result for those interested in translational applications as
it indicates that grade can be predicted based on data from
different technologies (microarray or RNA-seq) and using
different models (GGI or TG) with high concordance.
We also proposed a biomarker panel consisting of 34
genes for prediction of TG. Compared with other signa-
tures developed to predict grade, 15 of these 34 genes are
common with the 96 genes used in the calculation of the
GGI score [5]; none of them overlap with Ivshina’s five
genes [43]. A recently published paper [44] using TCGA
breast cancer RNA-seq data from 111 patients, developed
a nine-gene panel to differentiate HG1 andHG2, and a 19-
gene panel to classify HG2 and HG3. There is one gene
from the grade 34 panel in the set of nine genes, and
another one in the set of 19 genes. However, in this case it
is not surprising that there are few common genes with the
grade 34 panel since the models serve different purposes.
Our TG model and the 34-gene set were developed for
further stratifying HG2 tumours into poorly differentiated
and well-differentiated tumours.
RNA-seq also enables isoform-level expression , while
microarray quantification generally does not. In this study,
we found 2115 DE isoforms between HG1 and HG3 that
cannot be detected at the gene level. We also found that
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in 444 genes, isoforms of the same gene were associated
with HG in opposite directions. This phenomenon was
also observed in the TCGA data set. This indicates that
isoforms of the same gene might be involved in different
pathways conducting different functions. However, pre-
diction models based on isoform-level data did not pro-
vide improved classification accuracy, although we note
that classification between HG1 and HG3 groups is close
to being perfect based on gene-level data.
Our study also provided some insights into subcompo-
nents of HGs. There were significant differences between
the three components. There were 10,617 genes DE
between mitotic count scores 1 and 3. In contrast, there
were only 165 DE genes identified between nuclear pleo-
morphism scores 1 and 3. The three components also
contributed differently to the final prediction model. The
AUC of mitotic count is higher than tubularity or nuclear-
ity (0.92 versus 0.68 or 0.76), indicating that in the conven-
tional histologic grading system, the mitotic count score
has a stronger molecular signature at the RNA expression
level compared with the tubularity and nuclearity scores.
Conclusions
HG is an important indicator in routine breast cancer
diagnostics. However, it is imperfect for patient stratifica-
tion, particularly for patients with HG2 tumours. Here we
demonstrated that RNA-seq expression profiling at gene
and isoform level can be used to stratify HG2 tumours
into two distinct groups with different prognostic out-
comes, which has the potential to reduce both under- and
over-treatment of breast cancer patients.
Additional files
Additional file 1: All additional figures and tables listed. (PDF 488 kb)
Additional file 2: Includes lists of genes and coefficients of each model.
(XLSX 1361 kb)
Abbreviations
AUC: area under the ROC curve; CI: confidence interval; Clinseq: Clinical
Sequencing of Cancer in Sweden; CV: cross-validation; DE: differential
expression or differentially expressed; ER: oestrogen receptor; FDR, false
discovery rate; FISH: fluorescent in situ hybridisation; GGI: genomic grade
index; HER2: human epidermal growth factor receptor 2; HG: histologic grade;
HR, hazard ratio; PR: progesterone receptor; RFS: recurrence-free survival;
RNA-seq: RNA sequencing; ROC: receiver operating characteristic; TCGA: The
Cancer Genome Atlas; TG: transcriptomic grade.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MW analysed the data and drafted the manuscript. DK and MR contributed to
data analyses. MW, MR, DK, JL, KC and HG interpreted the results and edited
the manuscript. JL supervised data generation. MR designed the study and
supervised analyses. All authors read and approved the final manuscript.
Acknowledgements
We acknowledge funding from the Swedish Research Council
(Vetenskapsrådet – Unga forskare) and Swedish e-Science Research Centre
(SERC) – e-Science for Cancer Prevention and Control (ecpc).
Received: 11 March 2016 Accepted: 23 April 2016
References
1. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al.
Breast cancer prognostic classification in the molecular era: the role of
histological grade. Breast Cancer Res. 2010;12(4):207.
2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The
value of histological grade in breast cancer: experience from a large study
with long-term follow-up. Histopathology. 1991;19(5):403–10.
3. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The
value of histological grade in breast cancer: experience from a large study
with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991;19:
403–10. Histopathology. 2002;41:151.
4. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, et al.
Prognostic significance of Nottingham histologic grade in invasive breast
carcinoma. J Clin Oncol. 2008;26(19):3153–8.
5. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene
expression profiling in breast cancer: understanding the molecular basis
of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):
262–72.
6. Frierson Jr HF, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ,
Boyd JC, et al. Interobserver reproducibility of the Nottingham
modification of the Bloom and Richardson histologic grading scheme for
infiltrating ductal carcinoma. Am J Clin Pathol. 1995;103(2):195–8.
7. Robbins P, Pinder S, De Klerk N, Dawkins H, Harvey J, Sterrett G, et al.
Histological grading of breast carcinomas: a study of interobserver
agreement. Hum Pathol. 1995;26(8):873–9.
8. Zhao X, Rødland EA, Sørlie T, Vollan HK, Russnes HG, Kristensen VN,
et al. Systematic assessment of prognostic gene signatures for breast
cancer shows distinct influence of time and ER status. BMC Cancer.
2014;14(1):211.
9. Omenn GS, Guan Y, Menon R. A new class of protein cancer biomarker
candidates: differentially expressed splice variants of ERBB2 (HER2/neu)
and ERBB1 (EGFR) in breast cancer cell lines. J Proteome. 2014;107:103–12.
10. Narla G, DiFeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, et al. A
germline DNA polymorphism enhances alternative splicing of the KLF6
tumor suppressor gene and is associated with increased prostate cancer
risk. Cancer Res. 2005;65(4):1213–22.
11. Clinseq: Clinical Sequencing of Cancer in Sweden. http://clinseq.org/.
Accessed 14 Apr 2015.
12. Holm J, Humphreys K, Li J, Ploner A, Cheddad A, Eriksson M, et al. Risk
factors and tumor characteristics of interval cancers by mammographic
density. J Clin Oncol. 2015;33:1030–7.
13. KARMA (Karolinska Mammography Project for Risk Prediction of Breast
Cancer). http://karmastudy.org/sources/. Accessed 14 Apr 2015.
14. INCA (Information Network for Cancer Care). http://www.cancercentrum.
se/INCA/kvalitetsregister/Brostcancer/. Accessed 14 Apr 2015.
15. Regional Cancer Centre Stockholm-Gotland Area. http://www.
cancercentrum.se/sv/stockholmgotland/. Accessed 13 Apr 2015.
16. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. Star:
ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
17. Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with
high-throughput sequencing data. Bioinformatics. 2014;31:166–9.
18. Patro R, Mount SM, Kingsford C. Sailfish enables alignment-free isoform
quantification from RNA-seq reads using lightweight algorithms. Nat
Biotechnol. 2014;32(5):462–4.
19. Love MI, Huber W, Anders S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
20. Dillies MA, Rau A, Aubert J, Hennequet-Antier C, Jeanmougin M,
Servant N, et al. A comprehensive evaluation of normalization methods
for Illumina high-throughput RNA sequencing data analysis. Brief
Bioinform. 2013;14(6):671–83.
21. Robinson MD, McCarthy DJ, Smyth GK. Edger: a Bioconductor package
for differential expression analysis of digital gene expression data.
Bioinformatics. 2010;26(1):139–40.
Wang et al. Breast Cancer Research  (2016) 18:48 Page 13 of 13
22. Zou H, Hastie T. Regularization and variable selection via the elastic net.
J R Stat Soc Ser B Stat Methodol. 2005;67(2):301–20.
23. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized
linear models via coordinate descent. J Stat Softw. 2010;33(1):1.
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under
two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics. 1988;44:837–45.
25. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC:
an open-source package for R and S+ to analyze and compare ROC
curves. BMC Bioinform. 2011;12(1):77.
26. Cancer Genome Atlas Network. Comprehensive molecular portraits of
human breast tumours. Nature. 2012;490(7418):61–70.
27. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), et al. Effect of
radiotherapy after breast-conserving surgery on 10-year recurrence and
15-year breast cancer death: meta-analysis of individual patient data for
10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.
28. Therneau TM. A package for survival analysis in S. 2015. Version 2.38.
http://CRAN.R-project.org/package=survival. Accessed 20 Feb 2015.
29. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox
model. New York: Springer; 2000.
30. Law CW, Chen Y, Shi W, Smyth GK. Voom: precision weights unlock linear
model analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):29.
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J R Stat Soc Ser B Methodol.
1995;57:289–300.
32. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers
differential expression analyses for RNA-sequencing and microarray
studies. Nucleic Acids Res. 2015;43:e47.
33. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The
reactome pathway knowledgebase. Nucleic Acids Res. 2014;42(D1):472–7.
34. Yu G. Reactome pathway analysis. Homo. 2012;1266738:29.
35. Boyle EI, Weng S, Gollub J, Jin H, Botstein D, Cherry JM, et al.
Go::Termfinder—open source software for accessing gene ontology
information and finding significantly enriched gene ontology terms
associated with a list of genes. Bioinformatics 2004;20(18):3710–15.
36. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
J Clin Oncol. 2009;27(8):1160–7.
37. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer
types by shrunken centroids of gene expression. Proc Natl Acad Sci.
2002;99(10):6567–72.
38. Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast
cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev.
2012;38(6):698–707.
39. Wang SJ, Wong G, de Heer A-M, Xia W, Bourguignon LY. Cd44 variant
isoforms in head and neck squamous cell carcinoma progression.
Laryngoscope. 2009;119(8):1518–30.
40. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc
Series B Methodol. 1996;58:267–88.
41. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an
assessment of technical reproducibility and comparison with gene
expression arrays. Genome Res. 2008;18(9):1509–17.
doi:10.1101/gr.079558.108.
42. Wang Z, Gerstein M, Snyder M. RNA-seq: a revolutionary tool for
transcriptomics. Nat Rev Genet. 2009;10(1):57–63. doi: 10.1038/nrg2484.
43. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, et al. Genetic
reclassification of histologic grade delineates new clinical subtypes of
breast cancer. Cancer Res. 2006;66(21):10292–301.
44. Yao F, Zhang C, Du W, Liu C, Xu Y. Identification of gene-expression
signatures and protein markers for breast cancer grading and staging.
PLOS ONE. 2015;10(9):0138213.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
